Amivantamab FDA Approval Status
FDA Approved: No
Generic name: amivantamab
Treatment for: Non-Small Cell Lung Cancer
Amivantamab is an investigational, fully-human EGFR-MET bispecific antibody in development for the treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Development Timeline for amivantamab
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.